STUDY OF DURVALUMAB OR DURVALUMAB AND TREMELIMUMAB AS MAINTENANCE TREATMENT FOR PATIENTS WITH LIMITED STAGE SMALL-CELL LUNG CANCER WHO HAVE NOT PROGRESSED FOLLOWING CONCURRENT CHEMORADIATION THERAPY (ADRIATIC)
To assess the effectiveness, safety, and tolerability of using durvalumab alone as well as durvalumab in combination with tremelimumab in patients with Limited Stage- Small Cell Lung Cancer (LS - SCLC). This study will also compare any good and bad effects of durvalumab and tremelimumab to see if it improves the survival of patients with LD-SCLC, and if it can delay the progression of lung cancer when compared to placebo.
Limited Stage- Small Cell Lung Cancer
1. Male or female greater than 18 years old
2. Stage I-III Limited-stage Small Cell Lung Cancer (LS-SCLC)
3. Received 3 or 4 cycles of platinum-based chemotherapy at the same time as radiation therapy, which must be completed within 1-42 days prior to study entry
18 - 75
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug (s) until the disease progresses, treatment is no longer tolerable, or the participant and/or the study investigator decide to stop treatment, for up to 26 cycles (each cycle is 4 weeks long).
After finishing treatment, the study investigator will continue to watch participants for side effects and follow participant's condition until study completion.
Knight Clinical Trials Information Line